This feature highlights changes in clinical trial organizations’ personnel.

Acerus Pharmaceuticals

Acerus Pharmaceuticals has added Christopher Sorli to its staff as the company’s chief medical officer. Sorli was previously the vice president of U.S. medical affairs and head of cardiometabolic disease at Sanofi.

Adverum Biotechnologies

Thomas Kochy has been appointed vice president of commercial and program strategy at Adverum Biotechnologies. Kochy was recently a regional field director at Genentech.

Biogen

Biogen has named Michael McDonnell executive vice president and chief financial officer. Formerly, McDonnell was executive vice president and chief financial officer at IQVIA.

Circle Pharma

Rajinder Singh has been appointed chief science officer at Circle Pharma. Prior to this role, Singh was senior vice president of research and pharmaceutics at ChemoCentryx.

Citius Pharmaceuticals

Former Celgene vice president Myron Czuczman is now the chief medical officer at Citius Pharmaceuticals.

Cosette Pharmaceuticals

Apurva Saraf, a former Amneal Pharmaceutical executive, will now serve as president and CEO of Cosette Pharmaceuticals.

ELLKAY

ELLKAY has named Shreya Patel its chief innovation and product officer and Ajay Kapare its chief strategy and marketing officer. Patel most recently served as the company’s vice president of marketing and product, and Kapare was previously ELLKAY’s vice president of marketing and strategy.

ImmunoGen

Susan Altschuller has been tapped by ImmunoGen to serve as the company’s senior vice president and chief financial officer. Altschuller was recently the head of enterprise finance at Alexion Pharmaceuticals.

Kintai Therapeutics

Kintai Therapeutics has named Guillaume Pfefer, formerly the CEO-partner at Flagship Pioneering, CEO of the company. Scott Plevy has been named chief scientific officer of Kintai. Most recently, Plevy was the chief scientific officer of Senda Biosciences.

Kronos Bio

Barbara Kosacz has been appointed by Kronos Bio to the role of chief operating officer. Kosacz was most recently international head of Cooley’s life sciences practice.

Krystal Biotech

Krystal Biotech has appointed Whitney Ijem to the role of senior vice president of strategy and business development. Ijem previously served as managing director and senior biotechnology analyst of Guggenheim Securities.

Lixte Biotechnology

James Miser, previous president, CEO and chief medical officer of Seattle Children’s Hospital and City of Hope National Medical Center, will now serve as chief medical officer of Lixte Biotechnology.

MaaT Pharma

John Weinberg, former chief medical officer of 4D Pharma, has been appointed chief medical officer of MaaT Pharma.

Medicines360

Rolf Jansen has been appointed vice president of development and manufacturing of Medicines360. Most recently, Jansen was vice president of technical operations at Relypsa.

Notch Therapeutics

David Main has been appointed president and CEO of Notch Therapeutics. Main was recently CEO of Aquinox Pharmaceuticals.

Penumbra

Penumbra has named Corey Teigen chief science officer and James Benenati chief medical officer.

Replimune

Andrea Pirzkall has been appointed chief medical officer at Replimune. Formerly, Pirzkall was executive director of clinical development at BeiGene.

Rhythm Pharmaceuticals

David Meeker is now the CEO of Rhythm Pharmaceuticals. Previously, Meeker was president and CEO of KSQ Therapeutics.

Speranza Therapeutics

Arturo Taca, founder and medical director of INSynergy Drug and Alcohol Rehab Treatment Center, has been named medical director of Speranza Therapeutics.

Sun BioPharma

Sun BioPharma has named Jennifer Simpson president and CEO. Simpson most recently served as CEO of Delcath Systems.

Tarsus Pharmaceuticals

Sesha Neervannan has been appointed chief operating officer of Tarsus Pharmaceuticals. Formerly, Neervannan was senior vice president of global pharmaceutical development at Allergan. Additionally, Tarsus has named Leo Greenstein chief financial officer. Greenstein was most recently senior vice president of finance and corporate controller at Spectrum Pharmaceuticals.

Viroclinics

Davide Molho is the new CEO of Viroclinics. Molho was previously the CEO of Evolution Research Group.